

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Production, Demand and Key Producers, 2022-2028

<https://marketpublishers.com/r/G77EFF7BFAE0EN.html>

Date: December 2022

Pages: 129

Price: US\$ 4,480.00 (Single User License)

ID: G77EFF7BFAE0EN

Abstracts

Co-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.

This report studies the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics that contribute to its increasing demand across many markets.

The global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market size is expected to reach \$ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).

Highlights and key features of the study

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics total market, 2017-2028, (USD Million)

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics total market by region & country, CAGR, 2017-2028, (USD Million)

U.S. VS China: Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics total market, key domestic companies and share, (USD Million)

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics revenue by player and market share 2017-2022, (USD Million)

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics total market by Type, CAGR, 2017-2028, (USD Million)

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics total market by Application, CAGR, 2017-2028, (USD Million)

This reports profiles major players in the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include 1ST Biotherapeutics, 3B Pharmaceuticals, 3D-Micromac, 3DMed, 3D Systems, 10X Genomics, A*STAR Agency for Science, Technology and Research and A*STAR Institute of Microelectronics (IME), etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and

Diagnostics Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market, Segmentation by Type

Asset purchase

Assignment

Co-development

Co-market

Co-promotion

Collaborative R&D

Contract service

CRADA

Cross-licensing

Others

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market, Segmentation by Application

Industry sector

Therapy areas

Technology type

Deal components

Financial terms

Stage of development

Others

Companies Profiled:

1ST Biotherapeutics

3B Pharmaceuticals

3D-Micromac

3DMed

3D Systems

10X Genomics

A*STAR Agency for Science

Technology and Research

A*STAR Institute of Microelectronics (IME)

A2A Pharmaceuticals

Abbvie

AbCellera

ABL Bio

Abpro

Academy of Military Medical Sciences (China)

Accellix

Accord Healthcare

AccuGenomics

ACEA Biosciences

AC Immune

Acoustic MedSystems

Adaptimmune

Aduro BioTech

Advaxis

Adventus Ventures

Aerolase

Key Questions Answered

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Production, Demand an...

1. How big is the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market?
2. What is the demand of the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market?
3. What is the year over year growth of the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market?
4. What is the total value of the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market?
5. Who are the major players in the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

1.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction

1.2 World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size & Forecast (2017 & 2021 & 2028)

1.3 World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Total Market by Region

1.3.1 World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2017-2028)

1.3.2 United States Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028)

1.3.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028)

1.3.4 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028)

1.3.5 Japan Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028)

1.3.6 South Korea Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028)

1.3.7 ASEAN Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028)

1.3.8 India Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028)

1.4 Market Drivers, Restraints and Trends

1.4.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Drivers

1.4.2 Factors Affecting Demand

1.4.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Market Trends

1.5 Influence of COVID-19 and Russia-Ukraine War

1.5.1 Influence of COVID-19

1.5.2 Influence of Russia-Ukraine War

2 WORLD CO-DEVELOPMENT PARTNERING TERMS AND AGREEMENTS IN PHARMA, BIOTECH AND DIAGNOSTICS COMPANIES COMPETITIVE ANALYSIS

2.1 World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Player (2017-2022)

2.2 Industry Rank and Concentration Rate (CR)

2.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industry Rank of Major Players

2.2.2 Global Concentration Ratios (CR4) for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics in 2021

2.2.3 Global Concentration Ratios (CR8) for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics in 2021

2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Company Evaluation Quadrant

2.4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market: Overall Company Footprint Analysis

2.4.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market: Region Footprint

2.4.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market: Company Product Type Footprint

2.4.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market: Company Product Application Footprint

2.5 Competitive Environment

2.5.1 Historical Structure of the Industry

2.5.2 Barriers of Market Entry

2.5.3 Factors of Competition

2.6 Mergers, Acquisitions Activity

3 UNITED STATES VS CHINA VS REST OF THE WORLD

3.1 United States VS China: Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Comparison

3.1.1 United States VS China: Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Comparison (2017 & 2021 & 2028)

3.1.2 United States VS China: Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Market Share Comparison (2017 & 2021 & 2028)

3.2 United States Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Players and Market Share, 2017-2022

3.2.1 Major Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics in United States, Headquarters (States, Country)

3.2.2 United States Co-development Partnering Terms and Agreements in Pharma,

Biotech and Diagnostics Revenue by Domestic Player, (2017-2022)

3.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Players and Market Share, 2017-2022

3.3.1 Major Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics in China, Headquarters (Province, Country)

3.3.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Domestic Player, (2017-2022)

3.4 Rest of World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Players and Market Share, 2017-2022

3.4.1 Major Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics in Rest of World, Headquarters (State, Country)

3.4.2 Rest of World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Domestic Player, (2017-2022)

4 MARKET ANALYSIS BY TYPE

4.1 World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Overview by Type: 2017 VS 2021 VS 2028

4.2 Segment Introduction by Type

4.2.1 Asset purchase

4.2.2 Assignment

4.2.3 Co-development

4.2.4 Co-market

4.2.5 Co-promotion

4.2.6 Collaborative R&D

4.2.7 Contract service

4.2.8 CRADA

4.2.9 Cross-licensing

4.2.10 Others

4.3 Market Segment by Type

4.3.1 World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2017-2022)

4.3.2 World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2023-2028)

4.3.3 World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Market Share by Type (2017-2028)

5 MARKET ANALYSIS BY APPLICATION

5.1 World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Overview by Application: 2017 VS 2021 VS 2028

5.2 Segment Introduction by Application

5.2.1 Industry sector

5.2.2 Therapy areas

5.2.3 Technology type

5.2.4 Deal components

5.2.5 Deal components

5.2.6 Stage of development

5.2.7 Others

5.3 Market Segment by Application

5.3.1 World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2017-2022)

5.3.2 World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2023-2028)

5.3.3 World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2017-2028)

6 COMPANY PROFILES

6.1 1ST Biotherapeutics

6.1.1 1ST Biotherapeutics Details

6.1.2 1ST Biotherapeutics Major Business

6.1.3 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.1.4 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.1.5 1ST Biotherapeutics Recent Developments/Updates

6.1.6 1ST Biotherapeutics Competitive Strengths & Weaknesses

6.2 3B Pharmaceuticals

6.2.1 3B Pharmaceuticals Details

6.2.2 3B Pharmaceuticals Major Business

6.2.3 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.2.4 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.2.5 3B Pharmaceuticals Recent Developments/Updates

6.2.6 3B Pharmaceuticals Competitive Strengths & Weaknesses

6.3 3D-Micromac

6.3.1 3D-Micromac Details

6.3.2 3D-Micromac Major Business

6.3.3 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.3.4 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.3.5 3D-Micromac Recent Developments/Updates

6.3.6 3D-Micromac Competitive Strengths & Weaknesses

6.4 3DMed

6.4.1 3DMed Details

6.4.2 3DMed Major Business

6.4.3 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.4.4 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.4.5 3DMed Recent Developments/Updates

6.4.6 3DMed Competitive Strengths & Weaknesses

6.5 3D Systems

6.5.1 3D Systems Details

6.5.2 3D Systems Major Business

6.5.3 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.5.4 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.5.5 3D Systems Recent Developments/Updates

6.5.6 3D Systems Competitive Strengths & Weaknesses

6.6 10X Genomics

6.6.1 10X Genomics Details

6.6.2 10X Genomics Major Business

6.6.3 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.6.4 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.6.5 10X Genomics Recent Developments/Updates

6.6.6 10X Genomics Competitive Strengths & Weaknesses

6.7 A*STAR Agency for Science

6.7.1 A*STAR Agency for Science Details

6.7.2 A*STAR Agency for Science Major Business

6.7.3 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.7.4 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.7.5 A*STAR Agency for Science Recent Developments/Updates

6.7.6 A*STAR Agency for Science Competitive Strengths & Weaknesses

6.8 Technology and Research

6.8.1 Technology and Research Details

6.8.2 Technology and Research Major Business

6.8.3 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.8.4 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.8.5 Technology and Research Recent Developments/Updates

6.8.6 Technology and Research Competitive Strengths & Weaknesses

6.9 A*STAR Institute of Microelectronics (IME)

6.9.1 A*STAR Institute of Microelectronics (IME) Details

6.9.2 A*STAR Institute of Microelectronics (IME) Major Business

6.9.3 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.9.4 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.9.5 A*STAR Institute of Microelectronics (IME) Recent Developments/Updates

6.9.6 A*STAR Institute of Microelectronics (IME) Competitive Strengths & Weaknesses

6.10 A2A Pharmaceuticals

6.10.1 A2A Pharmaceuticals Details

6.10.2 A2A Pharmaceuticals Major Business

6.10.3 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.10.4 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.10.5 A2A Pharmaceuticals Recent Developments/Updates

6.10.6 A2A Pharmaceuticals Competitive Strengths & Weaknesses

6.11 Abbvie

- 6.11.1 Abbvie Details
- 6.11.2 Abbvie Major Business
- 6.11.3 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
- 6.11.4 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)
- 6.11.5 Abbvie Recent Developments/Updates
- 6.11.6 Abbvie Competitive Strengths & Weaknesses
- 6.12 AbCellera
 - 6.12.1 AbCellera Details
 - 6.12.2 AbCellera Major Business
 - 6.12.3 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
 - 6.12.4 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)
 - 6.12.5 AbCellera Recent Developments/Updates
 - 6.12.6 AbCellera Competitive Strengths & Weaknesses
- 6.13 ABL Bio
 - 6.13.1 ABL Bio Details
 - 6.13.2 ABL Bio Major Business
 - 6.13.3 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
 - 6.13.4 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)
 - 6.13.5 ABL Bio Recent Developments/Updates
 - 6.13.6 ABL Bio Competitive Strengths & Weaknesses
- 6.14 Abpro
 - 6.14.1 Abpro Details
 - 6.14.2 Abpro Major Business
 - 6.14.3 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
 - 6.14.4 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)
 - 6.14.5 Abpro Recent Developments/Updates
 - 6.14.6 Abpro Competitive Strengths & Weaknesses
- 6.15 Academy of Military Medical Sciences (China)
 - 6.15.1 Academy of Military Medical Sciences (China) Details
 - 6.15.2 Academy of Military Medical Sciences (China) Major Business
 - 6.15.3 Academy of Military Medical Sciences (China) Co-development Partnering

Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.15.4 Academy of Military Medical Sciences (China) Co-development Partnering

Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.15.5 Academy of Military Medical Sciences (China) Recent Developments/Updates

6.15.6 Academy of Military Medical Sciences (China) Competitive Strengths & Weaknesses

6.16 Accellix

6.16.1 Accellix Details

6.16.2 Accellix Major Business

6.16.3 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.16.4 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.16.5 Accellix Recent Developments/Updates

6.16.6 Accellix Competitive Strengths & Weaknesses

6.17 Accord Healthcare

6.17.1 Accord Healthcare Details

6.17.2 Accord Healthcare Major Business

6.17.3 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.17.4 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.17.5 Accord Healthcare Recent Developments/Updates

6.17.6 Accord Healthcare Competitive Strengths & Weaknesses

6.18 AccuGenomics

6.18.1 AccuGenomics Details

6.18.2 AccuGenomics Major Business

6.18.3 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.18.4 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.18.5 AccuGenomics Recent Developments/Updates

6.18.6 AccuGenomics Competitive Strengths & Weaknesses

6.19 ACEA Biosciences

6.19.1 ACEA Biosciences Details

6.19.2 ACEA Biosciences Major Business

6.19.3 ACEA Biosciences Co-development Partnering Terms and Agreements in

Pharma, Biotech and Diagnostics Product and Services

6.19.4 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.19.5 ACEA Biosciences Recent Developments/Updates

6.19.6 ACEA Biosciences Competitive Strengths & Weaknesses

6.20 AC Immune

6.20.1 AC Immune Details

6.20.2 AC Immune Major Business

6.20.3 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.20.4 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.20.5 AC Immune Recent Developments/Updates

6.20.6 AC Immune Competitive Strengths & Weaknesses

6.21 Acoustic MedSystems

6.21.1 Acoustic MedSystems Details

6.21.2 Acoustic MedSystems Major Business

6.21.3 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.21.4 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.21.5 Acoustic MedSystems Recent Developments/Updates

6.21.6 Acoustic MedSystems Competitive Strengths & Weaknesses

6.22 Adaptimmune

6.22.1 Adaptimmune Details

6.22.2 Adaptimmune Major Business

6.22.3 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.22.4 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.22.5 Adaptimmune Recent Developments/Updates

6.22.6 Adaptimmune Competitive Strengths & Weaknesses

6.23 Aduro BioTech

6.23.1 Aduro BioTech Details

6.23.2 Aduro BioTech Major Business

6.23.3 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.23.4 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.23.5 Aduro BioTech Recent Developments/Updates

6.23.6 Aduro BioTech Competitive Strengths & Weaknesses

6.24 Advaxis

6.24.1 Advaxis Details

6.24.2 Advaxis Major Business

6.24.3 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.24.4 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.24.5 Advaxis Recent Developments/Updates

6.24.6 Advaxis Competitive Strengths & Weaknesses

6.25 Adventus Ventures

6.25.1 Adventus Ventures Details

6.25.2 Adventus Ventures Major Business

6.25.3 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.25.4 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.25.5 Adventus Ventures Recent Developments/Updates

6.25.6 Adventus Ventures Competitive Strengths & Weaknesses

6.26 Aerolase

6.26.1 Aerolase Details

6.26.2 Aerolase Major Business

6.26.3 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

6.26.4 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022)

6.26.5 Aerolase Recent Developments/Updates

6.26.6 Aerolase Competitive Strengths & Weaknesses

7 RAW MATERIAL AND INDUSTRY CHAIN

7.1 Raw Material of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics and Key Manufacturers

7.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Manufacturing Costs

7.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Production Process

7.4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industrial Chain

8 DISTRIBUTION CHANNEL ANALYSIS

8.1 Distribution Channel Breakdown for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Shipments (%): 2017-2028

8.1.1 Direct Channel

8.1.2 Indirect Channel

8.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Typical Distributors

8.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Typical Customers

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2017, 2022 and 2028) & (USD Million)

Table 2. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2017-2022) & (USD Million)

Table 3. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2023-2028) & (USD Million)

Table 4. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Market Share by Region (2017-2022)

Table 5. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Market Share by Region (2023-2028)

Table 6. Major Market Trends

Table 7. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Player (2017-2022) & (USD Million)

Table 8. Revenue Market Share of Key Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players in 2021

Table 9. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industry Rank of Major Player, Based on Revenue in 2021

Table 10. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Company Evaluation Quadrant

Table 11. Head Office of Key Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Player

Table 12. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market: Company Product Type Footprint

Table 13. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market: Company Product Application Footprint

Table 14. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Mergers & Acquisitions Activity

Table 15. United States VS China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Comparison, (2017 & 2021 & 2028) & (USD Million)

Table 16. Major Player of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics in United States, Headquarters (States, Country)

Table 17. United States Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Domestic Player, (2017-2022) & (USD Million)

Table 18. United States Co-development Partnering Terms and Agreements in Pharma,

Biotech and Diagnostics Revenue Market Share by Domestic Player, (2017-2022)

Table 19. Major Player of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics in China, Company Headquarters (Province, Country)

Table 20. China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Domestic Player, (2017-2022) & (USD Million)

Table 21. China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Domestic Player, (2017-2022)

Table 22. Major Player of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics in Rest of World, Company Headquarters (State, Country)

Table 23. Rest of World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Domestic Player, (2017-2022) & (USD Million)

Table 24. Rest of World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Domestic Player, (2017-2022)

Table 25. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Type, (USD Million), 2017 & 2021 & 2028

Table 26. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Type (2017-2022) & (USD Million)

Table 27. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Type (2023-2028) & (USD Million)

Table 28. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Application, (USD Million), 2017 & 2021 & 2028

Table 29. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Application (2017-2022) & (USD Million)

Table 30. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Application (2023-2028) & (USD Million)

Table 31. 1ST Biotherapeutics Basic Information, Area Served and Competitors

Table 32. 1ST Biotherapeutics Major Business

Table 33. 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

Table 34. 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 35. 1ST Biotherapeutics Recent Developments/Updates

Table 36. 1ST Biotherapeutics Competitive Strengths & Weaknesses

Table 37. 3B Pharmaceuticals Basic Information, Area Served and Competitors

Table 38. 3B Pharmaceuticals Major Business

Table 39. 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

Table 40. 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 41. 3B Pharmaceuticals Recent Developments/Updates

Table 42. 3B Pharmaceuticals Competitive Strengths & Weaknesses

Table 43. 3D-Micromac Basic Information, Area Served and Competitors

Table 44. 3D-Micromac Major Business

Table 45. 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

Table 46. 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 47. 3D-Micromac Recent Developments/Updates

Table 48. 3D-Micromac Competitive Strengths & Weaknesses

Table 49. 3DMed Basic Information, Area Served and Competitors

Table 50. 3DMed Major Business

Table 51. 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

Table 52. 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 53. 3DMed Recent Developments/Updates

Table 54. 3DMed Competitive Strengths & Weaknesses

Table 55. 3D Systems Basic Information, Area Served and Competitors

Table 56. 3D Systems Major Business

Table 57. 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

Table 58. 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 59. 3D Systems Recent Developments/Updates

Table 60. 3D Systems Competitive Strengths & Weaknesses

Table 61. 10X Genomics Basic Information, Area Served and Competitors

Table 62. 10X Genomics Major Business

Table 63. 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

Table 64. 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 65. 10X Genomics Recent Developments/Updates
Table 66. 10X Genomics Competitive Strengths & Weaknesses
Table 67. A*STAR Agency for Science Basic Information, Area Served and Competitors
Table 68. A*STAR Agency for Science Major Business
Table 69. A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
Table 70. A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 71. A*STAR Agency for Science Recent Developments/Updates
Table 72. A*STAR Agency for Science Competitive Strengths & Weaknesses
Table 73. Technology and Research Basic Information, Area Served and Competitors
Table 74. Technology and Research Major Business
Table 75. Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
Table 76. Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 77. Technology and Research Recent Developments/Updates
Table 78. Technology and Research Competitive Strengths & Weaknesses
Table 79. A*STAR Institute of Microelectronics (IME) Basic Information, Area Served and Competitors
Table 80. A*STAR Institute of Microelectronics (IME) Major Business
Table 81. A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
Table 82. A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 83. A*STAR Institute of Microelectronics (IME) Recent Developments/Updates
Table 84. A*STAR Institute of Microelectronics (IME) Competitive Strengths & Weaknesses
Table 85. A2A Pharmaceuticals Basic Information, Area Served and Competitors
Table 86. A2A Pharmaceuticals Major Business
Table 87. A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
Table 88. A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 89. A2A Pharmaceuticals Recent Developments/Updates

Table 90. A2A Pharmaceuticals Competitive Strengths & Weaknesses
Table 91. Abbvie Basic Information, Area Served and Competitors
Table 92. Abbvie Major Business
Table 93. Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
Table 94. Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 95. Abbvie Recent Developments/Updates
Table 96. Abbvie Competitive Strengths & Weaknesses
Table 97. AbCellera Basic Information, Area Served and Competitors
Table 98. AbCellera Major Business
Table 99. AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
Table 100. AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 101. AbCellera Recent Developments/Updates
Table 102. AbCellera Competitive Strengths & Weaknesses
Table 103. ABL Bio Basic Information, Area Served and Competitors
Table 104. ABL Bio Major Business
Table 105. ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
Table 106. ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 107. ABL Bio Recent Developments/Updates
Table 108. ABL Bio Competitive Strengths & Weaknesses
Table 109. Abpro Basic Information, Area Served and Competitors
Table 110. Abpro Major Business
Table 111. Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
Table 112. Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 113. Abpro Recent Developments/Updates
Table 114. Abpro Competitive Strengths & Weaknesses
Table 115. Academy of Military Medical Sciences (China) Basic Information, Area Served and Competitors

Table 116. Academy of Military Medical Sciences (China) Major Business
Table 117. Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
Table 118. Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 119. Academy of Military Medical Sciences (China) Recent Developments/Updates
Table 120. Academy of Military Medical Sciences (China) Competitive Strengths & Weaknesses
Table 121. Accellix Basic Information, Area Served and Competitors
Table 122. Accellix Major Business
Table 123. Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
Table 124. Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 125. Accellix Recent Developments/Updates
Table 126. Accellix Competitive Strengths & Weaknesses
Table 127. Accord Healthcare Basic Information, Area Served and Competitors
Table 128. Accord Healthcare Major Business
Table 129. Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
Table 130. Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 131. Accord Healthcare Recent Developments/Updates
Table 132. Accord Healthcare Competitive Strengths & Weaknesses
Table 133. AccuGenomics Basic Information, Area Served and Competitors
Table 134. AccuGenomics Major Business
Table 135. AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services
Table 136. AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 137. AccuGenomics Recent Developments/Updates
Table 138. AccuGenomics Competitive Strengths & Weaknesses
Table 139. ACEA Biosciences Basic Information, Area Served and Competitors
Table 140. ACEA Biosciences Major Business

Table 141. ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

Table 142. ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 143. ACEA Biosciences Recent Developments/Updates

Table 144. ACEA Biosciences Competitive Strengths & Weaknesses

Table 145. AC Immune Basic Information, Area Served and Competitors

Table 146. AC Immune Major Business

Table 147. AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

Table 148. AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 149. AC Immune Recent Developments/Updates

Table 150. AC Immune Competitive Strengths & Weaknesses

Table 151. Acoustic MedSystems Basic Information, Area Served and Competitors

Table 152. Acoustic MedSystems Major Business

Table 153. Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

Table 154. Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 155. Acoustic MedSystems Recent Developments/Updates

Table 156. Acoustic MedSystems Competitive Strengths & Weaknesses

Table 157. Adaptimmune Basic Information, Area Served and Competitors

Table 158. Adaptimmune Major Business

Table 159. Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

Table 160. Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 161. Adaptimmune Recent Developments/Updates

Table 162. Adaptimmune Competitive Strengths & Weaknesses

Table 163. Aduro BioTech Basic Information, Area Served and Competitors

Table 164. Aduro BioTech Major Business

Table 165. Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product and Services

Table 166. Aduro BioTech Co-development Partnering Terms and Agreements in

Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share
(2017-2022) & (USD Million)

Table 167. Aduro BioTech Recent Developments/Updates

Table 168. Aduro BioTech Competitive Strengths & Weaknesses

Table 169. Advaxis Basic Information, Area Served and Competitors

Table 170. Advaxis Major Business

Table 171. Advaxis Co-development Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics Product and Services

Table 172. Advaxis Co-development Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) &
(USD Million)

Table 173. Advaxis Recent Developments/Updates

Table 174. Advaxis Competitive Strengths & Weaknesses

Table 175. Adventus Ventures Basic Information, Area Served and Competitors

Table 176. Adventus Ventures Major Business

Table 177. Adventus Ventures Co-development Partnering Terms and Agreements in
Pharma, Biotech and Diagnostics Product and Services

Table 178. Adventus Ventures Co-development Partnering Terms and Agreements in
Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share
(2017-2022) & (USD Million)

Table 179. Adventus Ventures Recent Developments/Updates

Table 180. Aerolase Basic Information, Area Served and Competitors

Table 181. Aerolase Major Business

Table 182. Aerolase Co-development Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics Product and Services

Table 183. Aerolase Co-development Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics Revenue, Gross Margin and Market Share (2017-2022) &
(USD Million)

Table 184. Co-development Partnering Terms and Agreements in Pharma, Biotech and
Diagnostics Raw Material

Table 185. Key Manufacturers of Co-development Partnering Terms and Agreements in
Pharma, Biotech and Diagnostics Raw Materials

Table 186. Co-development Partnering Terms and Agreements in Pharma, Biotech and
Diagnostics Typical Distributors

Table 187. Co-development Partnering Terms and Agreements in Pharma, Biotech and
Diagnostics Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Picture

Figure 2. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Total Market Size: 2017 & 2021 & 2028, (USD Million)

Figure 3. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Total Market Size (2017-2028) & (USD Million)

Figure 4. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Market Share by Region (2017-2028)

Figure 5. United States Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028) & (USD Million)

Figure 6. China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028) & (USD Million)

Figure 7. Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028) & (USD Million)

Figure 8. Japan Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028) & (USD Million)

Figure 9. South Korea Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028) & (USD Million)

Figure 10. ASEAN Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028) & (USD Million)

Figure 11. India Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028) & (USD Million)

Figure 12. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Drivers

Figure 13. Factors Affecting Demand

Figure 14. Producer Shipments of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics by Player Revenue (\$MM) and Market Share (%): 2021

Figure 15. Global Four-firm Concentration Ratios (CR4) for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Markets in 2021

Figure 16. Global Four-firm Concentration Ratios (CR8) for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Markets in 2021

Figure 17. United States VS China: Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Market Share Comparison (2017 & 2021 & 2028)

Figure 18. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type, (USD Million), 2017 & 2021 & 2028

Figure 19. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Market Share by Type in 2021

Figure 20. Asset purchase

Figure 21. Assignment

Figure 22. Co-development

Figure 23. Co-market

Figure 24. Co-promotion

Figure 25. Collaborative R&D

Figure 26. Contract service

Figure 27. CRADA

Figure 28. Cross-licensing

Figure 29. Others

Figure 30. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Market Share by Type (2017-2028)

Figure 31. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application, (USD Million), 2017 & 2021 & 2028

Figure 32. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Market Share by Application in 2021

Figure 33. Industry sector

Figure 34. Therapy areas

Figure 35. Technology type

Figure 36. Deal components

Figure 37. Financial terms

Figure 38. Stage of development

Figure 39. Others

Figure 40. World Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Market Share by Application (2017-2028)

Figure 41. Manufacturing Cost Structure Analysis of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics in 2021

Figure 42. Manufacturing Process Analysis of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Figure 43. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industrial Chain

Figure 44. Distribution Channel Breakdown for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Shipments (%): 2017-2028

Figure 45. Direct Channel Pros & Cons

Figure 46. Indirect Channel Pros & Cons

Figure 47. Methodology

Figure 48. Research Process and Data Source

I would like to order

Product name: Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Production, Demand and Key Producers, 2022-2028

Product link: <https://marketpublishers.com/r/G77EFF7BFAE0EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G77EFF7BFAE0EN.html>